Becton, Dickinson and Company (known as BDX) has been in a volatile spot with fluctuations in its share value continually hitting the news. Analysts have given the company an average rating of “Moderate Buy”, indicating their optimism. BDX reported exceeding Q2 Earnings Estimates, raising its Fiscal 2024 Guidance, and delivering sustained product demand. However, the firm also battled concerns over significant debt usage and a stagnated growth trajectory. Divesting activities were observed with JARISLOWSKY FRASER Ltd and Advisory Services Network LLC selling off considerable shares of BDX, and significant inside selling from executives Michael Garrison and Roland Goette. Despite financial prospects seeming robust, recent stock weakness has left investors nervous. Concerns rose with the company reporting lower-than-expected 2024 guidance and Q3 2025 EPS Estimates getting lowered by analysts. Despite difficulties, BDX was recognised among Fortune's Most Innovative Companies, reflecting its commitment to creativity and innovation. Dividend Aristocrats highlighted BDX for its consistent and reliable dividends, while the firm announced FDA clearance for a groundbreaking fingertip blood collection device. Several insiders, including Nomura Asset Management Co. Ltd., Franklin Resources Inc., and others, increased their stakes in BDX.
Becton Dickinson and BDX News Analytics from Mon, 24 Jul 2023 07:00:00 GMT to Tue, 28 May 2024 11:51:20 GMT -
Rating 2
- Innovation 5
- Information 7
- Rumor -1
